2024

Bollinger A, Hersberger KE, Meyer zu Schwabedissen HE, Allemann SS, Stäuble CK. Pharmacogenotyping disproves genetic cause of drug-related problems in family history: a case report. BMC Anesthesiol24, 416 (2024). doi:10.1186/s12871-024-02797-y. https://bmcanesthesiol.biomedcentral.com/articles/10.1186/s12871-024-02797-y

Wiss, F.M.; et al. (2024) “Overcoming Barriers: Strategies for Implementing Pharmacist-Led Pharmacogenetic Services in Swiss Clinical Practice”. Genes, 15, 862. Available at: https://doi.org/10.3390/genes15070862

Wiss F, Allemann S, Meyer zu Schwabedissen H, Stäuble C, Mikoteit T, Lampert M (2024). Recurrent high creatine kinase levels under clozapine treatment – a case report assessing a suspected adverse drug reaction. Frontiers in Psychiatry. 2024 April 29. https://doi.org/10.3389/fpsyt.2024.1397876

2023

Bollinger A, Stäuble CK, Jeiziner C, Wiss FM, Hersberger KE, Lampert ML, Meyer zu Schwabedissen HE, Allemann SS. Genotyping of Patients with Adverse Drug Reaction or Therapy Failure: Database Analysis of a Pharmacogenetics Case Series Study. Pharmgenomics Pers Med. 2023;16:693-706. https://doi.org/10.2147/PGPM.S415259

Bollinger A, Jeiziner C, Meyer Zu Schwabedissen HE, Hersberger KE, Allemann SS, Stäuble CK. Severe systemic adverse reactions to ophthalmic timolol in a CYP2D6 homozygous *4 allele carrier: a case report. Pharmacogenomics. 2023 Sep 15. https://doi.org/10.2217/pgs-2023-0122

Jeiziner, C., Meyer zu Schwabedissen, H.E., Hersberger, K.E. et al. Pharmacogenetic testing and counselling in the community pharmacy: mixed-methods study of a new pharmacist-led service. Int J Clin Pharm (2023). https://doi.org/10.1007/s11096-023-01596-8

2022

Wittwer, Nina L., et al. "Utilization of Drugs with Pharmacogenetic Dosing Recommendations in Switzerland: A Descriptive Study Using the Helsana Database." Pharmacogenomics and Personalized Medicine 15 (2022): 967-976. https://www.dovepress.com/utilization-of-drugs-with-pharmacogenetic-dosing-recommendations-in-sw-peer-reviewed-fulltext-article-PGPM

Stäuble CK, Jeiziner C, Bollinger A, Wiss FM, Hatzinger M, Hersberger KE, Ihde T, Lampert ML, Mikoteit T, Meyer zu Schwabedissen HE, Allemann SS. A Guide to a Pharmacist-Led Pharmacogenetic Testing and Counselling Service in an Interprofessional Healthcare Setting. Pharmacy. 2022; 10(4):86. https://doi.org/10.3390/pharmacy10040086

Stäuble, C.K., et al. "Case Report: Non-Response to Fluoxetine in a homozygous 5-HTTLPR S-Allele Carrier of the Serotonin Transporter Gene." Frontiers in Psychiatry: 1590. https://doi.org/10.3389/fpsyt.2022.942268

Jeiziner C, Allemann SS, Hersberger KE, Meyer zu Schwabedissen HE. Is Pharmacogenetic Panel Testing Applicable to Low-Dose Methotrexate in Rheumatoid Arthritis? – A Case Report. Pharmgenomics Pers Med. 2022;15:465-475. https://doi.org/10.2147/PGPM.S354011

2021

Stäuble, Céline K., et al. "Pharmacist-guided pre-emptive pharmacogenetic testing in antidepressant therapy (PrePGx): study protocol for an open-label, randomized controlled trial." Trials 22.1 (2021): 1-11.

Jeiziner C, Wernli, U, Suter K, Hersberger KE, Meyer zu Schwabedissen HE. HLA-associated adverse drug reactions - scoping review. Clin Transl Sci  2021. DOI: 10.1111/cts.13062. Publication

Jeiziner C, Stäuble CK, Lampert ML, Hersberger KE, Meyer zu Schwabedissen HE. Enriching medication review with a pharmacogenetic profile – a case of tamoxifen adverse drug reactions. Pharmgenomics Pers Med Vol. 24. DOI 10.2147/PGPM.S285807. Publication

Archiv

Stäuble CK, Lampert ML, Mikoteit T, Hatzinger M, Hersberger KE, Meyer zu Schwabedissen HE. Nonresponse to high-dose bupropion for depression in a patient carrying CYP2B6*6 and CYP2C19*17 variants: a case report. Pharmacogenomics Vol. 21, No 16. DOI: 10.2217/pgs-2020-0087. Publication

Jeiziner C, Suter K, Wernli U, Barbarino JM, Gong L, Whirl-Carrillo M, Klein TE, Szucs TD, Hersberger KE, Meyer zu Schwabedissen HE. Pharmacogenetic information in Swiss drug labels – a systematic analysis. Pharmacogenomics J 2020. DOI: 10.1038/s41397-020-00195-4. Publication